Clinical trials
Completed Phase 1/2 trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
424 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2002 | 4 |
| 2003 | 4 |
| 2004 | 3 |
| 2005 | 9 |
| 2006 | 13 |
| 2007 | 11 |
| 2008 | 17 |
| 2009 | 21 |
| 2010 | 27 |
| 2011 | 24 |
| 2012 | 38 |
| 2013 | 32 |
| 2014 | 27 |
| 2015 | 32 |
| 2016 | 32 |
| 2017 | 22 |
| 2018 | 23 |
| 2019 | 24 |
| 2020 | 21 |
| 2021 | 14 |
| 2022 | 11 |
| 2023 | 9 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 424 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Assistance Publique - Hôpitaux de Paris | 30 |
| Bristol-Myers Squibb | 20 |
| Novartis Pharmaceuticals | 19 |
| Hoffmann-La Roche | 14 |
| Nantes University Hospital | 10 |
| Groupe Francophone des Myelodysplasies | 9 |
| Merck Sharp & Dohme LLC | 8 |
| Pfizer | 8 |
| Institut National de la Santé Et de la Recherche Médicale, France | 7 |
| Sanofi | 7 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasms | 29 |
| Breast Neoplasms | 27 |
| Colorectal Neoplasms | 19 |
| Carcinoma, Non-Small-Cell Lung | 18 |
| Melanoma | 18 |
| Leukemia, Myeloid, Acute | 15 |
| Myelodysplastic Syndromes | 15 |
| Recurrence | 14 |
| Glioblastoma | 11 |
| Lymphoma, Non-Hodgkin | 11 |
Trials
Showing 1 to 25 of 424. Each trial links to its page on Pharma Observatory.
324 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.